This study is a component of an initial stage of at least 10 Phase I and II clinical trials of IMC-A12 sponsored by the Cancer Therapy Evaluation Program (CTEP) of the Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), to commence patient enrollment.
Contact: Roy Wu, Clinical Grants and Contracts Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer institute (NCI), 6130 Executive Boulevard, EPN Room 7009, Bethesda, MD 20892-7432 USA; Rockyville, MD 20852 (for express/courier service), 301-496-8866, fax: 301-480-4663, e-mail:wur@ctep.
NCI-Sponsored Studies More than 12 studies are currently being sponsored by the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) under a Clinical Trials Agreement with sanofi-aventis evaluating aflibercept as a single agent or in combination with chemotherapy regimens in a variety of cancer indications.
This study is one of at least 10 Phase I and II clinical trials of IMC-A12 sponsored by the Cancer Therapy Evaluation Program (CTEP) of the Division of Cancer Treatment and Diagnosis (DCTD), NCI, to commence patient enrollment.
Also, the Company announced that the Cancer Therapy Evaluation Program (CTEP) of the Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), has selected 10 proposals for Phase I/II clinical trials of IMC-A12.
Parkinson worked at the National Cancer Institute from 1990 to 1997, serving as Chief of the Investigational Drug Branch, then as Acting Associate Director of the Cancer Therapy Evaluation Program, before leaving for Novartis.
NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL) today announced that the Cancer Therapy Evaluation Program (CTEP) of the Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), has selected 10 proposals for Phase I/II clinical trials of ImClone Systems' anti-insulin-like growth factor-1 receptor (IGR-IR) monoclonal antibody known as IMC-A12.
